Evaluation of Serum 3-Bromotyrosine Concentrations in Dogs with Chronic Enteropathies
World Small Animal Veterinary Association World Congress Proceedings, 2015
P. Sattasathuchana1,2; J.S. Suchodolski1; J.M. Steiner1
1Veterinary Small Animal Clinical Sciences, Texas A&M University, College Station, TX, USA; 2Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand


3-bromotyrosine (3-BrY) is a stable byproduct of eosinophil activation. In dogs with chronic enteropathy (CE), eosinophils are considered to be the second most common type of inflammatory cell infiltrating the GI mucosa. We previously established and analytically validated a method for measurement of 3-BrY concentration in serum samples from dogs.


To evaluate serum 3-BrY concentrations in healthy dogs and dogs with CE.


Serum samples were collected from healthy dogs (n = 41) and dogs with CE (n = 30). 3-BrY concentrations were measured by electron ionization gas chromatography/mass spectrometry. Mann-Whitney U test was used to compare 3-BrY concentrations between healthy dogs and dogs with CE. A Spearman rank sum correlation coefficient (ρ) was used to determine the relationship between serum 3-BrY concentration and the severity of histopathologic lesions (based on the WSAVA GI histopathology grading guidelines) in dogs with CE.


Serum 3-BrY concentrations were significantly higher in dogs with CE (median [range]: 2.98 µmol/L [≤ 0.63–16.52 µmol/L]) than in healthy dogs (median [range]: 0.63 µmol/L [≤ 0.63–1.13 µmol/L]; p < 0.0001). There was a moderate correlation between serum 3-BrY concentrations and severity of eosinophilic infiltrates within the lamina propria in the region of the gastric fundus (ρ = 0.5466, p = 0.0126). Moreover, a strong positive correlation between serum 3-BrY concentrations and the severity of ileal crypt lesions was found (ρ = 0.9258, p = 0.0080).


Serum 3-BrY concentrations were significantly higher in dogs with CE when compared to healthy dogs. Utility of 3-BrY as a diagnostic and/or prognostic marker in dogs with CE should be further assessed.


Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.S. Suchodolski
Veterinary Small Animal Clinical Sciences
Texas A&M University
College Station, TX, USA

MAIN : Oral Abstracts : Serum 3-Bromotyrosine Concentrations
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.


777 W. Covell Blvd., Davis, CA 95616



  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357